ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years
Analía Meilerman Abuelafia
Matched on OpenAlex author ID A5084835361. Sources: OpenAlex.
Their work
- Papers
- 11 (first author 6, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 29
2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: 3 papers · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper
Papers 11
- Stage-resolved gene drivers of pancreatic ductal adenocarcinoma progression and therapeutic vulnerabilities. Co-author DOI 10.1016/j.isci.2026.115164↗
- KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2025.102421↗
- Priming therapy by targeting enhancer-initiated pathways in patient-derived pancreatic cancer cells. Co-author DOI 10.1016/j.ebiom.2023.104602↗
- Limitation and challenges in using pancreatic cancer-derived organoids as a preclinical tool. First author DOI 10.1002/cac2.12335↗
- Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity. First author DOI 10.1002/cac2.12365↗
- Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic prediction. First author DOI 10.1038/s41698-022-00299-z↗
- Targeting REG3β limits pancreatic ductal adenocarcinoma progression through CTGF downregulation. Co-author DOI 10.1016/j.canlet.2021.08.024↗
- Squamousness gain defines pancreatic ductal adenocarcinoma hepatic metastases phenotype, and gemcitabine response. First author DOI 10.1016/j.ejca.2021.06.038↗
- Evidencing a Pancreatic Ductal Adenocarcinoma Subpopulation Sensitive to the Proteasome Inhibitor Carfilzomib. First author DOI 10.1158/1078-0432.ccr-20-1232↗
- Expression of POU2F3 Transcription Factor Control Inflammation, Immunological Recruitment and Metastasis of Pancreatic Cancer in Mice. First author DOI 10.3390/biology9100341↗
- Dissecting the Anticancer Mechanism of Trifluoperazine on Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers11121869↗
Closest collaborators
The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Juan Iovanna · 11 shared papers, 2019–2026 · strength 1.76
- Paper KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adeno… DOI 10.1016/j.tranon.2025.102421↗
- Paper Limitation and challenges in using pancreatic cancer-derived organoids as a preclinical tool. DOI 10.1002/cac2.12335↗
- Paper Stage-resolved gene drivers of pancreatic ductal adenocarcinoma progression and therapeutic vulnerabilities. DOI 10.1016/j.isci.2026.115164↗
- Nicolas Alejandro Fraunhoffer · 10 shared papers, 2019–2026 · strength 1.64
- Paper KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adeno… DOI 10.1016/j.tranon.2025.102421↗
- Paper Limitation and challenges in using pancreatic cancer-derived organoids as a preclinical tool. DOI 10.1002/cac2.12335↗
- Paper Stage-resolved gene drivers of pancreatic ductal adenocarcinoma progression and therapeutic vulnerabilities. DOI 10.1016/j.isci.2026.115164↗
- Nelson Dusetti · 8 shared papers, 2020–2026 · strength 1.37
- Paper KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adeno… DOI 10.1016/j.tranon.2025.102421↗
- Paper Limitation and challenges in using pancreatic cancer-derived organoids as a preclinical tool. DOI 10.1002/cac2.12335↗
- Paper Stage-resolved gene drivers of pancreatic ductal adenocarcinoma progression and therapeutic vulnerabilities. DOI 10.1016/j.isci.2026.115164↗
- Eduardo Chuluyán · 6 shared papers, 2020–2026 · strength 0.99
- Paper KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adeno… DOI 10.1016/j.tranon.2025.102421↗
- Paper Stage-resolved gene drivers of pancreatic ductal adenocarcinoma progression and therapeutic vulnerabilities. DOI 10.1016/j.isci.2026.115164↗
- Paper Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity. DOI 10.1002/cac2.12365↗
- Raul A. Urrutia · 3 shared papers, 2022–2025 · strength 0.56
- Paper KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adeno… DOI 10.1016/j.tranon.2025.102421↗
- Paper Priming therapy by targeting enhancer-initiated pathways in patient-derived pancreatic cancer cells. DOI 10.1016/j.ebiom.2023.104602↗
- Paper Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic predict… DOI 10.1038/s41698-022-00299-z↗
- Gwen Alyce Lomberk · 3 shared papers, 2022–2025 · strength 0.56
- Paper KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adeno… DOI 10.1016/j.tranon.2025.102421↗
- Paper Priming therapy by targeting enhancer-initiated pathways in patient-derived pancreatic cancer cells. DOI 10.1016/j.ebiom.2023.104602↗
- Paper Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic predict… DOI 10.1038/s41698-022-00299-z↗
- Odile Gayet · 4 shared papers, 2020–2022 · strength 0.54
- Paper Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity. DOI 10.1002/cac2.12365↗
- Paper Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic predict… DOI 10.1038/s41698-022-00299-z↗
- Paper Squamousness gain defines pancreatic ductal adenocarcinoma hepatic metastases phenotype, and gemcitabine response. DOI 10.1016/j.ejca.2021.06.038↗
- Patricia Santofimia‐Castaño · 3 shared papers, 2019–2025 · strength 0.47
- Paper KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adeno… DOI 10.1016/j.tranon.2025.102421↗
- Paper Dissecting the Anticancer Mechanism of Trifluoperazine on Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers11121869↗
- Paper Evidencing a Pancreatic Ductal Adenocarcinoma Subpopulation Sensitive to the Proteasome Inhibitor Carfilzomib. DOI 10.1158/1078-0432.ccr-20-1232↗
- Daniel Grasso · 2 shared papers, 2025–2026 · strength 0.45
- Paper KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adeno… DOI 10.1016/j.tranon.2025.102421↗
- Paper Stage-resolved gene drivers of pancreatic ductal adenocarcinoma progression and therapeutic vulnerabilities. DOI 10.1016/j.isci.2026.115164↗
- Rémy Nicolle · 3 shared papers, 2021–2023 · strength 0.44
- Paper Priming therapy by targeting enhancer-initiated pathways in patient-derived pancreatic cancer cells. DOI 10.1016/j.ebiom.2023.104602↗
- Paper Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic predict… DOI 10.1038/s41698-022-00299-z↗
- Paper Squamousness gain defines pancreatic ductal adenocarcinoma hepatic metastases phenotype, and gemcitabine response. DOI 10.1016/j.ejca.2021.06.038↗
- Julie Roques · 3 shared papers, 2020–2022 · strength 0.41
- Paper Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity. DOI 10.1002/cac2.12365↗
- Paper Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic predict… DOI 10.1038/s41698-022-00299-z↗
- Paper Evidencing a Pancreatic Ductal Adenocarcinoma Subpopulation Sensitive to the Proteasome Inhibitor Carfilzomib. DOI 10.1158/1078-0432.ccr-20-1232↗
- Brice Chanez · 2 shared papers, 2022–2026 · strength 0.36
- Matías Estarás · 1 shared paper, 2025 · strength 0.25
- Ana Sahores · 1 shared paper, 2026 · strength 0.21
- Jonathan Garnier · 1 shared paper, 2026 · strength 0.21
- Oscar Mazza · 1 shared paper, 2026 · strength 0.21
- María Eugenia Pasqualini · 1 shared paper, 2026 · strength 0.21
- María Noé Garcia · 1 shared paper, 2026 · strength 0.21
- Agustín Yaneff · 1 shared paper, 2026 · strength 0.21
- Daniela Laura Papademetrio · 1 shared paper, 2026 · strength 0.21
- Pascal R. Hammel · 1 shared paper, 2026 · strength 0.21
- Michael T. Zimmermann · 1 shared paper, 2023 · strength 0.16
- Emma Folch‐Puy · 1 shared paper, 2021 · strength 0.15
- Daniel Closa · 1 shared paper, 2021 · strength 0.15
- Jerome F. Cros · 1 shared paper, 2021 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.